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Tumor cells in humans (1) and in experimental animals (2) possess unique antigens, called 
tumor-associated transplantation antigens ('rATA)  1,  to which tumor-bearing hosts respond. 
Individuals do not promptly and consistently reject their malignant tumor cells because TATA 
are relatively weak immunogens. Therefore, methods to increase the stimulatory capacity are 
being sought. 
Previously, it was demonstrated in our laboratory (3)  that  relatively weak immunogenic 
syngeneic plasmacytoma X5563 in C3H/He exclusively generated killer T-cell activity without 
inducing any significant helper T-cell activity against TATA. The failure to induce significant 
helper T-cell activity to TATA of X5563 in syngeneic system seems to be of vital importance 
in the following aspects. First, the X5563 syngeneic tumor system fails to provide double defense 
mechanisms of both cell-mediated and humoral immunity relating to the killer and helper T- 
cell generations, in sharp contrast to the allogeneic transplantation immunity. Furthermore, a 
failure to induce helper T-cell activity may have some relation to the lower level of generation 
of killer T-cell activity to syngeneic tumor cells in general. Cantor and Boyse (4, 5) reported 
that killer T-cell development against allogeneic tumor cells was augmented by the collaboration 
with other T-cell amplifier subsets which makes the Ly-specificity different from the killer T 
cells, and recognizes alloantigens other than those recognized by prekiiler T cells. Although the 
above selective generation of killer T cells against TATA indicates that the generation of helper 
T-cell activity against TATA may not be an absolute prerequisite for the effective development 
of killer T-cell responses, it is highly conceivable that  if the collaborative response of helper 
(amplifier) T cells with the prekiller cells can be successfully induced in syngeneic tumor system, 
the T-cell response against killer determinant may be augmented. In this context, if animals are 
immunized with tumor cells modified by additional antigenic determinants with which the 
helper (amplifier) T cells may be capable of reacting, the augmentation of specific killer T-cell 
response will be definitely expected. 
In the preceding experiments, a system was established to raise monospecific hapten-reactive 
T-lymphocyte activity, which enabled us to understand the basic mechanisms of regulatory T- 
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cell functions in the induction of immune responses (6-8), and may provide a great advantage 
in analyzing T-T-cell interaction (9, 10). 
The main advantages of the hapten-reactive T lymphocyte model are summarized as follows: 
(a) hapten-reactive T  lymphocytes are capable of reacting with the haptens coupled on any 
antigenic molecule such as on the allogeneic and syngeneic tumor cells. Thus, one can easily 
analyze the regulatory role of T cells for the induction of cell-mediated immunity to such cell- 
associated antigens.  (b) The helper and suppressor T-cell population can be raised against a 
simple hapten.  One can  analyze these antagonistic effects of T-cell populations on  various 
immune responses (9).  (c) Finally, as described before (7,  10), the hapten-reactive suppressor 
and helper T  lymphocytes can be specifically inactivated by the treatment with hapten-o-GL 
conjugate (copolymer of D-glutamic acid and D-lysine). The ample difference in susceptibility 
to the hapten-D-GL conjugate between helper and suppressor T lymphocytes can be applicable 
to the system where one desires to modify arbitrarily one of these activities. This system may be 
especially relevant to the establishment of a model system for manipulation of various immune 
responses to the appropriate directions, i.e., suppression or enhancement. 
In the present study, 2,4,6-trinitrophenyl (TNP)-residue was introduced to the surface of 
tumor cells as additional determinants, and hapten-reactive T  lymphocyte activity was gener- 
ated in mice by immunization with TNP-derivatized isologous mouse gamma globulin (MGG). 
Amplifying effect of TNP-reactive T  cells on the tumor-specific killer T-cell-generation was 
analyzed by immunizing with TNP-derivatized tumor cells. The results will show the augmen- 
tation of induction of tumor-specific immunity by hapten-reactive T-cell activity, and provide 
evidence that appropriate manipulations designed to induce additional determinant-reactive 
helper (amplifier) T  lymphocytes afford a  potentially effective mode of immunoprophylaxis 
against the tumor. 
Materials and  Methods 
Mice.  C3H/He  and C57BL/6  mice of both sexes, originally obtained from The Jackson 
Laboratory (Bar Harbor, Maine) and maintained in our Institute, were used at 7-9 wk of age. 
Antigens and Preparation of Hapten-Carrier Conjugates.  Keyhole limpet hemocyanin (KLH) was 
purchased from Calbiochem, San  Diego, Calif., and human  gamma globulin (HGG), Cohn 
fraction II was obtained from Nutritional Biochemical Corporation, Cleveland, Ohio. Mouse 
gamma globulin (MGG) was prepared from pooled serum of normal C3H/He and C57BL/6 
mice by precipitation with 40%  saturated ammonium sulfate and  purified through diethyl- 
aminoethyl cellulose column chromatography with 0.015  M  sodium phosphate buffer, pH 8.0. 
The o-GL was obtained from Pilot Chemicals, Inc., Watertown, Mass. The polymer had an 
average tool wt of 27,000 and a ratio of glutamic acid to lysine residues of 60:40. 
The following TNP-conjugates were prepared by using sodium 2,4,6-trinitrobenzene sulfo- 
nate:  TNPs2-HGG,  TNP27-MGG(C57BL/6),  TNP3o-MGG(C3H/He),  TNPsT-D-GL,  and 
TNP2o-KLH.  Subscripts  refer  to  the  average  number  of TNP  groups  per molecule of the 
proteins, and these were calculated from the absorption reading at 348 nm. 
Benzylpenicilloyl (BPO)-KLH was prepared by reacting 100 mg of KLH with  100  mg of 
benzylpenicillin in 5 mi borate-buffered saline at pH 9.0 adjusted with 1 N NaOH. 14 molecules 
of BPO-group were found  to bind covalently with  1 molecule of KLH as measured by the 
penamaldate  method.  BPO14-MGG(C57BL/6)-TNP27,  BPOxs-MGG(C3H/He)-TNP3o,  and 
BPO14-KLH-TNP~0 were prepared from TNP27-MGG(C57BL/6), TNP3o-MGG(C3H/He), and 
TNP~0-KLH by further reacting with benzylpenicillin as described above. 
In the above calculations of numbers of haptens per molecule of carrier, the mol wt of KLH, 
MGG, and HGG were taken as 100,000,  160,000, and  160,000, respectively. 
Assay System for  Measuring the  Helper and Suppressor Actwities of TNP-Reactive T  Lymphocyte 
Populations.  Mice were immunized by intraperitoneal (i.p.) injection of 100 #g of syngeneic 
TNP-MGG in complete Freund's adjuvant (CFA). 3-8 wk after the immunization, single-cell 
suspensions were prepared from the spleens of these primed mice in Eagle's minimal essential 
medium (MEM), and used as the source of TNP-reactive T  cells. Single-cell suspensions from 
spleens of mice which had been immunized i.p. 8-10 wk earlier with  100 #g of BPO-KLH in 
CFA were used as responding B  cells, and  transferred intravenously (i.v.)  into 600  rads X- 
irradiated recipients together with TNP-MGG-primed cells. In other experiments, these TNP- HAMAOKA ET AL.  187 
MGG-primed mice were directly X-irradiated and transferred with BPO-KLH-primed cells. 
For measuring the helper T-cell activity secondary antigenic challenges were performed by i.p. 
injection of 100 #g of BPO-MGG-TNP immediately after the cell transfer. 
For measuring the suppressor T-cell activity, the above adoptively transferred recipient mice 
were i.p. challenged with BPO-KLH-TNP (9). 
Helper  and  suppressor  T-cell activities in  the  TNP-MGG-primed cell  population were 
detected by the magnitude of anti-BPO antibody responses of transferred BPO-specific B cells 
as compared with those in the presence of normal cells.  Anti-BPO antibody responses  were 
measured  by  hemolytic plaques  in  recipient's spleens  7  days  after  adoptive  transfer  and 
antigenic stimulation. 
Hemolytic Plaque Assay.  Anti-BPO plaque-forming cells  (PFC)  in the spleens of recipient 
mice were counted by using a modification of Cunningham's hemolytic plaque technique as 
described previously (9). Since the number of direct PFC was always negligible, only indirect 
PFC are listed in the Results. 
Treatment for  T-CeU Deprwation.  Mice were thymectomized at 6 wk and injected i.p.  with 
0.25 ml of anti-thymocyte serum (ATS) 5 d after thymectomy. ATS was prepared according to 
the two-pulse method introduced by Medawar and Levey (11), except that immunization  was 
made  with  the  thymocytes from  C3H/He  rather  than  from  CBA  mice.  Efficiency of this 
procedure for T-cell deprivation was evaluated by determining  both the susceptibility  of spleen 
cells to anti-Thy-1 antiserum and guinea pig complement treatment and antibody response to 
thymus-independent  antigen 5 days after the administration of ATS. 
Antibody  Response to  Thymus-Independent Antigen.  c-Amino-dinitrophenyl-lysine-substituted 
dextran (DNP-dextran) was prepared by using a modification of the method of Fielder et al. 
(12), as described previously (13). After i.v. injection of 200 pg of DNP-dextran, direct anti- 
DNP PFC in the spleens were enumerated 5 d  later. For the assay,  sheep erythrocytes were 
conjugated with DNP-BSA by using CrCIa as described previously (9). 
Induction of Tumor-Specific Immunity.  As a tumor, spontaneously occurring X5563 plasmacy- 
toms, derived from C3H/He strain and maintained by serial i.p. passages  into syngeneic mice 
in ascitic form, was  used. This tumor cell  is free of surface immunoglobulin as  detected by 
fluorescent antibody technique. 107-3 X  107 of TNP-derivatized tumor cells as described below 
were  inoculated i.p.  to  induce specific  immunity against  tumor.  For  detecting protective 
immunity against tumor, 106 of viable unmodified tumor cells were challenged intradermally 
(i.d.). 
Trinitrophenylation of Tumor Cells.  TNP-derivatized tumor cells were prepared according to 
the method described by Philpott et al.  (14). Briefly,  100  X  106 tumor cells pretreated with 
mitomycin C at a concentration of 40/~g/ml for 50 min at 37°C were suspended in 100 ml of 
Hanks' balanced salt solution containing 300 lag/ml of sodium TNP sulphonate. After 30 min 
incubation at 37°C, the tumor cells were washed twice and viability  of the cells was determined 
by trypan blue dye exclusion test. By this system, more than 90% of the tumor cells were viable 
after coupling with TNP. 
Assay System for Killer  T-Cell Activity.  Cytotoxicity assay,  originally devised by Hashimoto 
and Sudo (15) was utilized with a slight modification into microculture-plate system.  Radio- 
labeling of tumor cells was performed by incubation rocking of a  suspension of 3  ×  106 of 
tumor cells in 3 ml of RPMI-1640 medium containing 10% heat-inactivated fetal calf serum 
(RPMI-FCS) and 1/tCi of [SH]uridine (the Radiochemical Centre, Amersham, England) (sp 
act  2.9 Ci/mmol) in a  Falcon 3002  tissue culture dish, at  37°C for 60 min. After extensive 
washings, 3  ×  104 of radiolabeled target tumor cells suspended in 0.1 mi of RPMI-FCS were 
distributed into each well of a  Falcon 3040 microplate, and mixed together with the graded 
numbers (75-300 X  104) of normal or immunized spleen cells suspended in 0.1 ml of RPMI- 
FCS. After effector to target interaction was proceeded for 6 h at 37°C in 5% CO2/air, the cells 
in each well were harvested and washed twice with a large volume of cold 5% trichloroacetic 
acid  solution to eliminate all the  radioactivity associated with  killed target  cells,  and  the 
radioactivity remaining in the viable target cells was measured in a liquid scintillation  counter. 
Cytotoxicity index (percentage specific  killing) was  calculated as:  percentage specific  killing 
=  (I  -  [cpm in the immune well/cpm in the normal well])  ×  100%, where the normal or 
immune well denotes target cells incubated with normal or immune spleen cells. In the above 
eytotoxicity test, the values listed in the Results represent the mean of four immune wells and 188  HAPTEN-TATA  T-T-CELL  INTERACTION 
the final target cell viability in the normal wells was usually in the range of 95-100% of that at 
the initiation of the assay. 
In our previous study (16), it was established that the cytotoxic activity detected in X5563- 
C3H/He combination was mediated exclusively by killer T lymphocytes but not by antibody- 
dependent  K-cell activities or cytotoxic macrophages. 
Measurement of Tumor Growth.  Tumor growth was measured  by quantitation of myeloma 
protein  in sera of tumor-inoculated  mice with radial  immunodiffusion  technique  utilizing 
rabbit anti-idiotypic antibody (17). 
Results 
Generation of TNP-Reactive  Helper  T-Cell Activity  by  TNP-MGG-Priming.  Previously, 
it was demonstrated that hapten-reactive helper T  cells could be raised in mice by 
immunization with hapten-derivatized isologous MGG  (6-8).  These helper T  cells 
collaborate  with  another  hapten-specific  B  lymphocyte at  the  stimulation  with 
isologous MGG derivatized with double haptens of distinct specificities. Consistent 
with  the  previous  observations,  as  shown  in  Table  I,  TNP-reactive  helper  T-cell 
activity was  raised  in  C57BL/6  mice by  immunization with TNP-MGG  and  the 
activity was detected by transferring BPO-specific B cells into 600 rads X-irradiated 
TNP-MGG-primed mice and stimulating with BPO-MGG-TNP (group II). 
The failure to detect such helper activity in MGG-primed mice suggests the TNP- 
specificity of helpers (group III). The helper activity in TNP-MGG-primed mice was 
not detected by the stimulation with BPO-MGG (not conjugated with TNP), further 
indicating the TNP-reactivity of such  helper cells  (data not listed).  Moreover, the 
failure to detect such TNP-reactive helper cell activity in TNP-HGG-primed recipi- 
ents  (group IV)  is reminiscent of the previous observation  (7)  that  hapten-reaetive 
helper T-cell activity could not be raised in mice by the immunization with hapten- 
heterologous  protein  conjugates.  This  also  indicates  that  TNP-primed  B  cells  or 
circulating anti-TNP-antibodies are not responsible for these helper cell activities. 
In this experiment, because the helper cell activity was detected in heavily irradiated 
TNP-MGG-primed  mice,  it  can  be  also  concluded  that  TNP-reactive  helper  cell 
activity is radioresistant. 
Amplifying Effect  of TNP-MGG-Priming on the Generation of Cytotoxic T  Lymphocytes to 
AUoantigen at the Immunization  with  TNP-Modified Allogeneic  Tumor  Cells.  To test the 
TABLE I 
Generation of TNP-Reactive Helper T-CeU Activity by Immunization with TNP-MGG* 
Exp. group 
Anti-BPO anti- 
C57BL/6 mice  Responding B cells  2nd Ag  body response 
primed with  transferred  (PFC/spleen):~: 
I  None  335 (1.43) 
II  TNP-MGG  C57BL/6  BPO-MGG-TNP  4,062 (1.06) 
III  MGG  BPO-KLH-  886 (1.46) 
IV  TNP-HGG  Primed cells  518 (1.47) 
* C57BL/6 mice were primed by i.p. injection of either 100/xg of  TNP-MGG (C57BL/6), MGG (C57BL/6), 
or TNP-HGG in CFA 6 wk before cell transfer. Those primed mice and other ~g~oup of nonimmunized 
normal mice were X-irradiated (600  rads) and then injected i.v. with 50  ×  l0  of BPO-KLH-primed 
spleen cells. All recipients were stimulated i.p. with 100/~g of BPO-MGG-TNP. The BPO-KLH-primed 
spleen cells came from syngeneic donors which had been immunized with 100/xg of BPO-KLH in CFA 
8 wk previously. 
:~ The values denote geometric means and standard errors in  the recipient spleens 7 days after the cell 
transfer. Numbers in parentheses represent standard errors. HAMAOKA  ET AL, 
TABLE II 
Amplifying Effect of TNP-MGG-Priming on the Generation of Cytotoxic T 
Lymphocytes to Alloantigen at the Immumzation with TNP-Modified Allogeneic 
Tumor Cells* 
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Exp. 
group 
C57BL/6 mice treated with  Killer T-cell activity 
Tumor-immuniza-  Hapten-priming  tion  X5563  TNP-X5563:~ 
% 
I  CFA  TNP-X5563  0  0 
II  TNP-MGG  TNP-X5563  40  50 
III  MGG  TNP-X5563  0  3 
IV  TNP-HGG  TNP-X5563  2  2 
V  TNP-MGG  None  3  6 
* C57BL/6 mice were preimmunized with TNP-eonjugates as indicated, and 6 wk 
later 107 of TNP-derivatized X5563 cells (C3H/He origin) were i.p. injected. 1 wk 
after the tumor-immunization, cytotoxic killer T-cell activities of spleen cells were 
measured against X5563 and TNP-X5563 at target to effector cell ratio of 1:50. 
The values represent percent specific killing to respective targets. 
effect of TNP-MGG-priming on the generation of alloantigen-reactive  killer T  lym- 
phocytes  subsequent  to  the  immunization  with  TNP-derivatized  allogeneic  tumor 
cells, 107 of TNP-derivatized X5563 (C3H/He origin) were injected i.p. into C57BL/6 
mice 6 wk after the TNP-MGG, MGG, or TNP-HGG-priming. As shown in Table II, 
killer T  cells to the allogeneic tumor cells were not induced  in CFA-primed control 
animals by the immunization with TNP-X5563 in this experimental condition (group 
I).  On  the  other  hand,  TNP-MGG-preimmunization  apparently  augmented  the 
generation  of killer  T  cells  to  the  allogeneic  X5563  tumor  cells  (group  II).  Other 
preimmunization  regimens  such  as  of MGG  or TNP-HGG  revealed  no significant 
enhancing effects (groups III and IV), indicating that the preimmunization regimen 
which generates the TNP-reactive helper T-cell activity as in Table I was a prerequisite 
for  this  augmentation.  The  specificity  of these  cytotoxic  killer  T  cells  is  directed 
mainly to alloantigens on X5563 and was verified by the comparable cytotoxicity to 
unmodified X5563 and TNP-modified X5563 cells. 
Radioresistant Nature of Amplifying Activity in  TNP-MGG-Primed Mice on the Generation of 
Killer T  Lymphocytes.  It was not certain whether TNP-reactive amplifying activity in 
the TNP-MGG-primed  mice was equivalent  to the TNP-reactive helper activity for 
the induction of antibody responses which had been shown in Table I. However, it 
was revealed that TNP-reactive amplifier activity had the same functional property 
as  helper  activity  with  respect  to  its  radiation  resistance.  C57BL/6  mice  were 
immunized with TNP-MGG  in CFA or only CFA as control. 6  wk later,  half of the 
mice in. each group was 600 rads X-irradiated  and reconstituted  with  l0  s of normal 
spleen cells as the responder killer cell source, and the other half was nonirradiated. 
The irradiated  and nonirradiated  mice were then  immunized  two times every week 
with 2  ×  107 of TNP-conjugated X5563. 7 d after the last immunization, killer T  cell 
activities against allogeneic X5563 tumor cells were tested at a target to effector ratio 
of 1:50. 
As shown in Table III, it is noticeable that the comparable augmentation by TNP- 
MGG-preimmunization was elicited irrespective of whether or not these TNP-MGG- 190  HAPTEN-TATA T-T-CELL INTERACTION 
TABLE III 
Radioresistant Nature of Amplifying Activity in TNP-MGG-Primed  Mice on the 
Generation of Killer T Lymphocytes* 
C57BL/6  Mice treated with 
Killer T-cell 
Hapten-derivatized  activity 
Hapten-priming  X-irradiation  tumor-immuniza-  X5563 
tion 
% 
CFA~  TNP-X5563  25.2 
TNP-MGGJ  None  TNP-X5563  48.0 
CFA~  600 rads X-irradiated~ and  TNP-X5563  31.2 
TNP-MGGJ  reconstituted with normal  TNP-X5563  57.2 
spleen cells 
* C57BL/6 mice were preimmunized with 100 #g of TNP-MGG (C57BL/6) in CFA 
or CFA alone as control 6 wk previously. 600 rads X-irradiation of those primed 
animals and reeonstitution with  10  s of normal spleen cells were performed imme- 
diately before the TNP-tumor immunization.  Killer T-cell activities generated  in 
those animals against allogeneic X5563 cells were tested at target to effector ratio 
of 1:50, 7 days after the two consecutive weekly immunizations with 2 ×  107 TNP- 
X5563. 
In a separate experiment,  proliferating  activity of lymphocytes in host was com- 
pletely lost by this dose of X-irradiation as assessed by mixed lymphocyte reactivity 
to alloantigens. 
primed mice received whole body X-irradiation. Thus, the amplifying effect of TNP- 
MGG-preimmunization is radioresistant, and  functionally similar to the helper cell 
activity (18). 
Requirement of T-Cell Population for Amplifying Activity in  TNP-MGG-Primed  Mice.  To 
ascertain further T  lymphocytes in TNP-MGG-primed  mice mediating this amplified 
generation of killer T  cells, T-cell-deprived C57BL/6  mice were prepared with adult 
thymectomy  (ATX)  plus anti-thymocyte serum  (ATS)-treatment, and  primed with 
TNP-MGG  as above. The efficiency of the methods used here for T-cell depletion was 
determined by measuring the quantity ofThy-1-positive cells remaining in the spleen 
5  d  after T-cell depletion. As shown  in Table IV, the number of Thy-l-positive cells 
decreased in (ATX  +  ATS)-treated mice, whereas B-cell activity was not affected, as 
evident  from  the  direct  anti-DNP  antibody  responses  to  the  thymus-independent 
antigen, DNP-dextran. 
Normal  or  those  T-cell-deprived mice  were  primed  with  TNP-MGG,  and  6  wk 
later, 600  rads X-irradiated and  reconstituted i.v. with  l0  s of normal spleen cells as 
the responder killer T-cell source. TNP-X5563  tumor cell-immunization was started 
immediately after the cell transfer, and boosted  1 wk later. As the results are shown 
in Table IV, the amplifying effect of TNP-MGG-priming  on the generation of killer 
T  cells as demonstrated in normal animals  (group II) was not observed in  (ATX  + 
ATS)-treated  group  (group  III).  It  can  be  concluded,  therefore,  that  the  T-cell 
population  in  TNP-MGG-primed  mice  plays a  crucial  role in  the  amplification of 
generation of killer T-cell activity in  the above allogeneic host-tumor combination. 
Marginal Augmentation of Killer T-Cell Development against  TA TA  by the Immunization 
with  TNP-Modified  Syngeneic Tumor Cells to  TNP-MGG-Preimmunized  Mice.  While the 
TNP-MGG-primed  allogeneie C57BL/6  mice clearly augmented  the  generation  of 
cytotoxic T  cells to the C3H/He  plasmacytoma by immunization with TNP-modifi- HAMAOKA  ET  AL. 
TABLE  IV 
Failure to Detect the Amplifying Effect of TNP-MGG-Priming  on the Generation of Cytotoxic T 
Lymphocytes in T Cell-Deprived Mice 
191 
Susceptibil- 
ity of spleen  B-cell response 
cells to anti- 
against DNP-  TNP-MGG- 
Exp.  C57BL/6 Mice  Thy-1 anti-  dextran:]:  primin~ 
group  sera and  Anti-DNP 
comple-  PFC/spleen 
ment* 
Killing 
TNP-X5563  Killer T-cell 
immuniza-  activity 
tion  X5563 
%  % 
I  Normal  --  --  No  Yes  18.5 
II  Normal  26.3 (100)  42,300 (1.t6)  Yes  Yes  46.5 
III  ATX  +  ATS [I  1.8 (6.8)  40,780  (1.25)  Yes  Yes  21.2 
* Thy-1 positivity was determined in the spleen 5 d after the injection of ATS. The values represent the 
means of three mice. 
Normal or T-cell-deprived mice were immunized i.v. with 200 #g of thymus-independent antigen, DNP- 
dextran, 5 d after the injection of ATS. After 5 d, direct anti-DNP PFC in the spleen were measured and 
expressed as the geometric means of four animals. 
§ Normal or T-cell-deprived mice were 600 rads X-irradiated and reconstituted with 10  s of normal spleen 
cells,  followed  by the priming with TNP-MGG. 6 wk later, all mice were immunized i.p.  with  l07 of 
TNP-X5563, and boosted 7 d later. Killer T-cell activity was measured 7 d after the last immunization 
at target to effector ratio of 1:50. 
H  C57BL/6 mice were thymectomized at 6 wk and injected i.p. with 0.25 ml ofATS 5 d after thymectomy. 
TABLE  V 
Marginal Augmentation of Killer T-Cell Generation against X5563 TA TA by 
Hapten- TA TA Cooperation* 
C3H/He Mice treated with  Killer T-cell activity 
Hapten-priming  Hapten-derivatized tu-  X5563  TNP-X5563 
mor-immunization 
% 
CFA  TNP-X5563  9  8 
TNP-MGG  TNP-X5563  15  23 
* C3H/He  mice which had been preimmunized with  100 #g of TNP-MGG 
(C3H/He)  in CFA or CFA alone 8 wk previously were immunized with 3 
×  107 of TNP-X5563  (syngeneic tumor)  four times i.p.  at 2-wk  intervals. 
Cytotoxicity assay was performed 2 wk after the last immunization at target 
to effector cell ratio of t:100. 
cation, it was investigated whether  syngeneic C3H/He  mice can  also respond  to the 
same TNP-derivatized  tumor  cells with this TNP-MGG-preimmunization.  As one of 
the typical  results is shown  in Table  V,  the preimmunization  with TNP-MGG  only 
slightly  augmented  the  generation  of  killer  T  cells  against  TATA  at  repeated 
immunization  with  TNP-modified  tumor  cells.  However,  such  amplifying  effect  of 
TNP-MGG-preimmunization  on  the killer T  lymphocytes  in syngeneic combination 
was not consistently reproduced  in all the experiments. It was assumed that coexistence 
of TNP-reactive  suppressor T-cell activities in those TNP-MGG  immunized  mice may 
diminish  or  interfere  with  the  TNP-reactive  helper  (amplifier)  T-cell  activities  as 
described  in  the  previous  report  (10).  In  the  following  section,  a  trial  was  made  to 
eliminate the suppressor T-cell activity from TNP-reactive  T-lymphocyte  populations. 
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TABLE VI 
Selective Inhibition of Generation of TNP-Reactive Suppressor T-Cell Activity by TNP-D-GL-Pretreatment 
and Resulting Augmented Generation of TNP-Reactive Helper T-Cell Activity* 
Condition for generation of TNP-reactive  Anti-BPO antibody  re*ponse 
T cell in C3H/He Mice 
2nd Ag (activity 
Responding cells  Exp. group  detected) 
TNP-t>-GL pretreat-  Hapten-priming  PFC/spleen  Index 
merit 
BPO-KLH-primed  cells  I  None  CFA]  1,656 (1.22)  1.00 
II  None  TNP-MGG~  BPO-MGG-TNP  3,084 (1.26)  1.86 
III  500 ~g TNP-o-GL  TNP-MGGJ  (Helper)  8,577 (1.01)  5.18 
IV  None  CFA]  58,504 (I.09)  1.00 
V  None  TNP-MGG[  BPO-KLH-TNP  21,926 (1.17)  0.37 
VI  500/.tg TNP-D-GL  TNP-MGGJ  (Suppress)  51,423 (1.24)  0.88 
* C3H/He mice were either  pretreated  with TNP-n-GI,  3 days before TNP-MGG  (C3H/He)-immunization  or not  pretreated.  The TNP- 
reactive helper and suppressor T-cell activities generated  in  these TNP-MGG-primed  mice were me~ured  3 wk after  the TNP-MGG- 
immunization  by transferring their spleen cells into other 600 fads X-irradiated  recipient mice together with BPO-KLH-prirned cells and 
stimulating  with  100/xg of BPO-MGG-TNP or BPO-KLH-TNP.  The BPO-KLH-primed  cells came from another  donor mice which had 
been immunized  10 wk previously. 
Pretreatment and Resulting Augmented Generation of TNP-Reactive Helper  T-Cell Activity  in 
TNP-MGG-Preimmunized Mice. Previously (10)  it was found that hapten-reactive sup- 
pressor T-cell activity was  more sensitive to the inactivation by hapten-conjugated 
nonimmunogenic copolymer, D-GL, than helper T  cells.  Moreover, the inhibition of 
suppressor T-cell generation by the pretreatment with hapten-conjugated D-GL before 
the immunization of hapten-isologous protein conjugate resulted in an augmentation 
of the  development of hapten-reactive helper  T-cell  activity.  Consistent  with  the 
previous observations, as shown in Table VI, TNP-reactive helper T-cell activity was 
clearly augmented by the treatment of TNP-D-GL before TNP-MGG immunization 
(comparison  between  groups  II  and  III).  The  notion  that  augmentation  of TNP- 
reactive helper T-cell activity was due to the inhibition of generation of TNP-reactive 
suppressor  T  ceils  by TNP-D-GL-treatment, was  substantiated  by the  comparison 
between groups V  and VI. As shown in group V, anti-BPO antibody responses were 
substantially lower than  group IV  (control), and  this reduction as reflected by the 
TNP-reactive suppressor T-cell activity in TNP-MGG-primed cell population was not 
observed in the cell population pretreated with TNP-D-GL before TNP-MGG-priming 
(group VI). 
Although the data are not shown here, that the relevant cells in TNP-MGG-primed 
cell population mediating the TNP-reactive helper and suppressor functions are T 
cells, and not B cells, was indicated by the following two experimental results. First, 
TNP-MGG-primed  spleen  cells  were  depleted  of  B  cells  by  treatment  with  an 
antiserum specific for antigens on the surface of mouse B cells, known as anti-Th-B 
(19). The almost complete reduction of B-cell activity in the anti-Th-B treated TNP- 
MGG-primed spleen cells contrasts sharply with the intact helper and suppressor cell 
activities. Second, the TNP-MGG-primed spleen cells were treated with either normal 
mouse serum plus C  or anti-Thy-l,2 antiserum plus C.  Both helper and suppressor 
cell  activities  were  almost  completely  abolished  by  treatment  with  anti-Thy-l,2 
antiserum  plus  C.  These results were exactly in  corroboration with  those  in  para- 
azobenzoate  reactive  T  cells  as  demonstrated  previously  (9).  Thus,  helper  and 
suppressor  cell  activities  developed  by  immunization  with  TNP-MGG  were  both 
mediated by Thy-l-positive T  lymphocytes. HAMAOKA ET AL. 
TABLE VII 
Amplifying Effect of TNP-o-GL-pretreatment on the Generation of Killer T Cells to Syngeneic 
Tumor Cells in the Process of Hapten- TA TA T- T Cell Interactions* 
193 
Exp. group 
Conditions for generation of TNP-reactive T 
ceils in C3H/He mice 
TNP-n-GL-pretreat ment  Hapten-priming 
Hapten-derivatized  Killer  T-cell 
tumor-immuniza-  activity 
tion  X5563 
% 
I  None  CFA  TNP-X5563  0.5 
II  None  TNP-MGG  TNP-X5563  8.4 
III  500 #g TNP-D-GL  TNP-MGG  TNP-X5563  47. I 
* C3H/He mice either pretreated with TNP-D-GL 3 d earlier or not pretreated were immunized 
with  100 #g of TNP-MGG  (C3H/He)  in CFA. Sham-immunized mice (group I) received CFA 
alone. 6 wk thereafter, those mice were immunized i.p. with  107 of TNP-derivatized syngeneic 
tumor cells once a week for .5 wk, and killer T lymphocyte activities generated in the spleens were 
measured 7 d after the last immunization at target to effector cell ratio of 1:100. 
In conclusion, the selective elimination  of suppressor T  cells by TNP-o-GL-treat- 
ment resulted in an augmented helper T-cell activity. 
Amplification of Generation of Tumor-Specific Killer T Lymphocyte Activity by Suppressor T- 
Cell-Depleted Hapten-Reactive T Lymphocytes.  Having established a reproducible system 
for a  potent induction of TNP-reactive helper T  lymphocytes in C3H/He  mice, the 
feasibility  of utilizing  this  helper T-cell system  to  facilitate  development  of tumor- 
specific immunity was explored.  The TNP-derivatized  X5563 as above was used as 
an immunizing antigen and the capacity of recipient  mice to develop tumor-specific 
cytotoxic  T  cells  was  tested  depending  on  whether  or  not  such  mice  had  been 
preimmunized  in a  manner to develop potent  TNP-reactive helper T-cell activities. 
The results are summarized in Table VII. C3H/He  mice preimmunized  with TNP- 
MGG 6 wk previously and repeatedly immunized with TNP-conjugated tumor ceils 
(group  II)  developed  specific  cytotoxic  activity  only  marginally  higher  than  that 
observed in sham  (CFA)-preimmunized control mice (group I). In contrast, the mice 
which had been immunized with TNP-MGG in conjunction with TNP-D-GL in such 
a manner as to develop more potent TNP-reactive helper T-cell activities (group III), 
generated a  striking magnitude of killer T-cell activity. 
Augmenting Effect of TNP-D-GL-Pretreatment in TNP-MGG-Primed Mice on the Development 
of Tumor-Specific lmmune Resistance.  The obvious aim of this type of approach was to 
develop an effective method  for substantially  improving host  anti-tumor  immunity 
against  growth of syngeneic tumors. The following results indicate that it is possible 
to improve anti-tumor immunity by this method as reflected by a  significant prolon- 
gation  of host  survival  after  inoculation  of lethal  viable  tumor  cells.  Thus,  the 
experimental  protocol followed substantially  the same as Table VII, except  that the 
mice were challenged i.d. with lethal  doses (106)  of X5563 cells 7 days after the last 
TNP-derivatized tumor-immunization. These results are summarized in Fig.  1. Thus, 
sham  (CFA)-immunized  (group I)  as well as TNP-MGG-immunized C3H/He  mice 
without TNP-o-GL-pretreatment  (group II) failed to develop any appreciable tumor- 
specific immune-capability  after immunization with TNP-derivatized  X5563 synge- 
neic tumor cells. On the other hand, the mice (group III), which had generated potent 
TNP-reactive helper T-cell activity with TNP-D-GL pretreatment before TNP-MGG- 
priming  displayed  higher  levels  of immune  resistance  against  the  challenge  with 194  HAPTEN-TATA  T-T-CELL  INTERACTION 
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FIG.  1.  Augmenting  effect  of TNP-D-GL-pretreatment  on  the  development  of  tumor-specific 
immunity in hapten-TATA T-T-ceU interactions. Experimental protocol was substantially the same 
as Table VII, except that the mice were challenged i.d. with lethal dose (10  e') of viable syngeneic 
X5563 tumor cells 7 days after the last TNP-derivatized tumor-immunization. Tumor-growth was 
quantitatively determined by the concentration of myeloma protein in serum, and this was measured 
by utilizing anti-idiotypic antibody to X5563  myeloma protein. Group I  (C)), group II  (B), and 
group III (&), received exactly the same pretreatments and immunizing regimens as in Table VII, 
respectively. Individual values of tumor growth in each group, and geometric means and standard 
errors are illustrated. The ultimate tumor-death values in groups I, II, and III were 7/7, 7/7, and 
5/8, and mean survival times (days) of dead animals in those groups were 17.8 +  0.70, 16.3 ","  1.02, 
and 25.1:1:  1.31, respectively. 
viable  tumor,  and  the  growth  of challenged  tumor  was  significantly suppressed. 
Moreover, as shown by mortality values of the respective groups summarized in the 
legend of Fig. 1, mice subjected to this preimmunization regimen are also appreciably 
improved in terms of their capacity to resist tumor growth after inoculation of a lethal 
dose of such viable tumor cells, and in the significant number of animals (three out 
of eight) the challenged tumor regressed. Thus, the above results clearly indicate that 
appropriate manipulations designed to induce the potent hapten-reactive helper T- 
lymphocyte activity provide a  very effective mode of immunopotentiation against 
tumor. 
Discussion 
The  use  of chemically  modified  tumor  cells  to  be  treated  for  specific,  active 
immunization has been  receiving considerable attention. The attractiveness of this 
approach stems from its potential for both therapy and prophylaxis. The theoretical 
framework for the role of cell co-operation in tumor immunity, and speculations on 
manipulations that might augment tumor rejection have been presented by Mitchison HAMAOKA ET AL.  195 
(20).  His work showed that  the  immunogenicity of tumor antigens  might  be aug- 
mented by coupling new helper antigens such as haptens, proteins, new transplanta- 
tion antigens, viral coat antigens, or xenogeneic cell antigens to tumor cell surfaces. In 
the past decade a variety of experimental observations suggested that such a mecha- 
nism may indeed result in increased resistance to in vivo tumor growth. Martin et al. 
(21)  were able to detect a  slight but significant increased cell-mediated cytotoxicity 
for native tumor cells in the spleens of C57BL/6 mice immunized with concanavalin 
A-or dinitrophenylaminocaproate-coated EL-4 cells.  Hashimoto and Yamanoha (22) 
also reported that C57BL/6 mic.e immunized with EL-4 cells coupled with fluorescent 
dansyl  group  in  aqueous  medium  by dansyl chloride-cyclohepta amylose complex 
aquired transplantation immunity specific for the tumor cells.  Likewise, Galili et al. 
(23) demonstrated that trinitrophenylated Moloney virus-induced YAC cells induced 
a  higher cytotoxic antibody response and better protection against  small tumor cell 
doses in syngeneic, low responsive strain A  mice than  nonmodified YAC cells that 
had been inactivated by irradiation or mitomycin C treatment. These results indicated 
that low responsiveness of syngeneic hosts to the tumor antigens can be overcome, at 
least to some extent, by coupling the immunizing tumor cells to a strong immunogenic 
hapten,  yet we believe that  the mechanisms  remain obscure, and  the  augmenting 
activity is not consistently high enough. 
In the present study, we studied the above notion more directly by using hapten- 
TATA T-T-cell collaboration system for the induction of tumor-specific transplanta- 
tion immunity. TNP-residue was introduced on the surface of tumor cells as additional 
determinants  because  haptenation  with  TNP  could  be  achieved  with  minimum 
denaturation  of cell-surface  component  and  TNP-reactive  helper  T  lymphocyte 
activity was easily generated in mice by immunization with TNP-derivatized MGG. 
Thus,  the  amplifying effect of TNP-reactive helper T  cells on the TATA-reactive 
killer T-cell-generation could be easily analyzed by immunizing with TNP-derivatized 
tumor cells. 
In a  combination of C57BL/6 mice and TNP-modified X5563 allogeneic tumor, 
TNP-MGG-preimmunization which successfully generated the TNP-reactive helper 
T-cell activity (Table I) augmented the generation of killer T  cells to the allogeneic 
X5563  tumor cells  (Table II).  An  allogeneic model  system was  used  to study  the 
optimal conditions for the chemical modification procedure of the tumor cells and 
appropriate immunization regimens. Based on the positive augmenting effect of TNP- 
MGG-priming, the same principle was applied  to the syngeneic combination. The 
result  (Table  V)  demonstrated  that  the  preimmunization  with  TNP-MGG  only 
slightly  augmented  the  generation  of  killer  T  cells  against  TATA  at  repeated 
immunization with the same TNP-modified X5563 cells. However, such amplifying 
effect of TNP-MGG-preimmunization  on  the  killer T-cell generation  in  syngeneic 
combination was rather weak, and not always reproduced in all the experiment. In 
the  allogeneic combination,  it  has  been established  that  amplifier T  cells directed 
against  lymphocyte-defined determinants of H-2 complex collaborate with killer T 
cells directed against serologically-defined determinant  (24). When a  new antigenic 
determinant (TNP) was introduced on the surface of allogeneic cells and immunized 
in the presence of TNP-reactive helper T cells, it is conceivable that the TNP-reactive 
T cells collaborate with such amplifier T cells responsible for generation of alloantigen- 
reactive killer T  cells besides the collaboration with killer T  cells, and resulted in an 
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syngeneic system, the killer T cells are only the relevant cell type reactive with TATA 
of X5563 as mentioned earlier (3), and TNP-reactive T  cells may solely function as 
amplifier  T  cells  for  the  generation  of killer  T  cells.  This  possible  mechanistic 
distinction may explain the difference in augmenting effect of TNP-reactive T  cells 
on the generation of killer T  lymphocytes between allogeneic and syngeneic combi- 
nations. 
The  other  possible  reason  for  the  weak  augmenting effect of sole  TNP-MGG- 
priming  on  the  generation  of TATA-specific  killer  T  lymphocytes  in  syngeneic 
combination,  is  that  the  coexistence  of TNP-reactive  suppressor  T-cell  activities 
generated in the TNP-MGG-preimmunized mice may diminish or interfere with the 
potential  activities of TNP-reactive  helper T-cell  population.  Previously  (10),  the 
influence of inhibiting suppressor T-cell generation on the development of helper T 
cells was analyzed with respect to hapten-specificity of the latter's responsiveness. The 
functional specificity of helper T-cell activity could be quantitatively measured by 
the responses of a hapten-reactive T-cell population to various haptenic determinants 
of structurally-related compounds. The conclusion that suppressor T  cells generated 
during the  primary  immune  response  ultimately exert  an  effect on  helper T-cell 
development derived from the following observations:  (a)  that the development of 
helper T-cell  activity was substantially augmented  in  the hapten-D-GL-pretreated 
animals in which the generation of suppressor T-cell activity was completely inhibited; 
and (b) that the hapten-reactive T  lymphocyte populations developed in the absence 
of suppressor T  cells have a unique quality of their higher specificity and affinity for 
haptenic determinants to which they have been primed. 
Consistent with the previous observations (10),  in the present study the ability of 
TNP-I)-GL-treatment to selectively inactivate TNP-reactive suppressor T-cell activity 
was  also  demonstrated by  the  type of experiment  summarized  in  Table  VI,  and 
resulted  in  a  striking  increase  in  helper  T-cell  activity.  Corroboration  with  this 
augmented helper T-cell generation, the immunization with TNP-modified syngeneic 
tumor cells into such animals resulted in the striking levels  of generation of specific 
cytotoxic T-cell  activity  (Table  VII),  and  the  corollary  protective  effect  of such 
treatment as is illustrated by the significant prolongation of survival in animals after 
inoculation of a lethal dose of viable tumor cells (Fig.  1). These results clearly indicate, 
therefore, that appropriate manipulations designed to induce potent hapten-reactive 
helper T lymphocyte activity can be established to provide a potentially very effective 
mode of immunoprophylaxis against syngeneic tumor cells'. 
Although it  is not yet certain  from the present  study whether or not  the TNP- 
reactive amplifier T  cells  responsible for augmentation of tumor-specific immunity 
are equivalent to the helper T cells for triggering B lymphocytes, those T-cell activities 
are functionally indentical at least with respect to the following two properties: both 
activities are  (a)  X-irradiation-resistant, and  (b)  resistant  to TNP-D-GL-treatment. 
The  precise  characterization  of such  amplifier  T  cells  is  under  progress  in  our 
laboratory. 
Finally, it may be of value to mention that the obvious goal of the application of 
hapten-reactive T-cell activity to the tumor system is to develop an effective mode of 
immunotherapy to substantially improve host anti-tumor immunity against already 
growing tumors. For example, if one wishes to induce effective host resistance against 
already growing tumor in this system, one approach would be to attempt to preim- 
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appropriate pretreatment with the relevant hapten-v-GL copolymer, followed at some 
later time by immunization of the individual with hapten-coupled attenuated tumor 
cells. As demonstrated in the present experiments, it would be reasonable to assume 
that the hapten-reactive T  ceils induced by previous immunization in this manner 
facilitated the development of tumor-specific cytotoxic T lymphocytes and resulted in 
tumor rejection.  However, further experiments to demonstrate the above hapten- 
reactive  helper  T-cell  system to  suppress  the  already growing  tumor  have  been 
unsuccessful. The development of tumor-specific cytotoxic T lymphocytes was signif- 
icantly depressed  in the X5563  tumor-bearing animals, and the mechanism for this 
depression  was ascribed to the presence  of large quantities of tumor antigen derived 
from the tumor mass. Experimentally, this was induced by the repeated pretreatment 
with MMC-attenuated tumor cells (not conjugated with hapten), and this treatment 
significantly inhibited the development of tumor-immunity even after appropriate 
tumor immunization procedures.  Thus, the pre or coexistence of inappropriate form 
of TATA inhibits the subsequent induction of anti-tumor immunity, and this sup- 
pressive mechanism is operating in the specific immunosuppression of tumor-bearing 
animals (16). 
Based  on  the  above  consideration,  we  explored  the  feasibility of utilizing the 
hapten-reactive helper T  lymphocyte system to the prevention of this type of sup- 
pression.  If one can prevent the killer T-ceU suppression  induced by the presence  of 
inappropriate form of TATA with the hapten-reactive helper T-cell activities, this 
approach may provide some premise for circumvention of tumor-specific immuno- 
depression  frequently observed  in tumor-bearing animals. The results 2 revealed that 
the supplement of hapten-reactive T  cells to the system at the pretreatment with 
MMC-attenuated tumor cells  with  haptenation  invariably inhibited  this  type of 
suppression  for induction of killer T lymphocytes, and turn the negative signal of this 
pretreatment to positive stimulus as demonstrated here. Thus, it is logical to conclude 
that approaches leading to direct amplification of effector activity on one hand, and 
to depletion of suppressive  effects  on  the other, by hapten-reactive T-lymphocyte 
activity, may be one of the most direct routes to augment overall anti-tumor responses 
and for the immunotherapy of cancer. 
Summary 
2,4,6-trinitrophenyl (TNP)-reactive T-cell activities were raised in mice by immu- 
nization with TNP-isologous mouse gamma globulin. After establishing that TNP- 
reactive T  lymphocytes can serve as amplifier cells for induction of killer T  lympho- 
cytes in allogeneic system, we explored the possibility  of this hapten-reactive T-cell 
system to amplify tumor-specific killer T-lymphocyte activity in the syngeneic system. 
We utilized relatively weak immunogenic syngeneic plasmacytoma X5563 in C3H/He 
mice. 
Analysis  of the TNP-reactive T-cell  activities revealed that such T  lymphocytes 
express the biological  functions of both major subtypes of regulatory T  cells, namely 
suppressors and helpers, and that TNP-reactive suppressor and helper T lymphocytes, 
respectively,  differ in  their relative susceptibility to  specific  inactivation by TNP 
2 T. Hamaoka et al. Regulatory functions of hapten-reactive helper and suppressor T  lymphocytes. IV. 
Prevention of tolerance induction in killer T cell lineage against tumor-specific transplantation antigen by 
supplement of hapten-reactive helper T cell activities. Manuscript in preparation. 198  HAPTEN-TATA T-T-CELL INTERACTION 
conjugates  of the  nonimmunogenic  D-amino acid  copolymer, D-glutamic acid,  and 
o-lysine (D-GL). By taking advantage of the relative susceptibility-difference to TNP- 
D-GL,  selective  inactivation  of  TNP-reactive  suppressor  T  cells  was  induced  by 
appropriate treatment with TNP-D-GL, and the generation of TNP-reactive helper 
T-cell activity was amplified. 
The supplement of augmented TNP-reactive helper T-cell activity to the system at 
the immunization with syngeneic X5563 with TNP-haptenation, resulted in a striking 
augmentation  of induction  of tumor-specific  killer  T-lymphocyte  activity,  and  a 
considerable number of hosts survived after the challenge with lethal dose of viable 
tumor cells. 
Thus, appropriate manipulations designed to induce potent hapten-reactive helper 
T lymphocytes provided the potential for a very effective mode ofimmunoprophylaxis 
against tumor. 
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